1380292-86-3

Basic information

• Product Name: 1-fluoro-4-(1-methoxy-2-methylpropan-2-yl)benzene
• Synonyms: 1-fluoro-4-(1-methoxy-2-methylpropan-2-yl)benzene
• CAS NO: 1380292-86-3
• Molecular Weight: 182.238
• Mol File: 1380292-86-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-fluoro-4-(1-methoxy-2-methylpropan-2-yl)benzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-fluoro-4-(1-methoxy-2-methylpropan-2-yl)benzene(1380292-86-3)
• EPA Substance Registry System: 1-fluoro-4-(1-methoxy-2-methylpropan-2-yl)benzene(1380292-86-3)

Safety Data

• Hazardous Substances Data: 1380292-86-3(Hazardous Substances Data)

Upstream product

• 703-10-6 2,2-Dimethyl-2-(4-fluorophenyl)ethanol 
• 74-88-4 methyl iodide 

Downstream Products

• 1380292-88-5 1-fluoro-4-(1-methoxy-2-methylpropan-2-yl)-2-nitrobenzene 
• 1380292-90-9 1-azido-4-(1-methoxy-2-methylpropan-2-yl)-2-nitrobenzene 
• 1380292-92-1 4-(1-methoxyl-2-methylpropan-2-yl)benzene-1,2-diamine 
• 1380351-15-4 3-[3-({[(3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyl-tetrahydro-2H-furo[3,4-d][1,3]dioxol-4-yl]methyl}(methyl)amino)cyclobutyl]-N-[2-amino-4-(1-methoxy-2-methylpropan-2-yl)phenyl]propanamide 

Relevant articles and documents

Purine compound containing bicyclic group, and preparation method thereof

The invention provides a purine compound containing a bicyclic group which is shown as a formula (I) and a formula (II) and a pharmaceutically acceptable salt, and a preparation method thereof. The compound is an inhibitor of histone methyltransferase DOT1L, and can be used for treating diseases caused by the abnormity of enzyme activity, such as tumor.

SUBSTITUTED PURINE AND 7 - DEAZAPURINE COMPOUNDS AS MODULATORS OF EPIGENETIC ENZYMES

The present invention relates to substituted purine and 7-deazapurine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOTl -mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.